Among seniors with diagnosed diabetes, roughly 20.8% are using GLP-1 injectables. It is a key part of addressing their health concerns. While the weight loss medications have dominated headlines, many of the drugs have remained out of reach (financially) under Medicare rules.
That is finally starting to change thanks to Medicare’s new GLP-1 Bridge program, which launches in July 2026 and temporarily expands access to certain obesity medications for eligible beneficiaries. The new initiative is designed to serve as a transition into Medicare’s longer-term BALANCE program, helping older Americans gain access to treatments that were previously excluded from standard coverage. For retirees struggling with obesity-related health conditions like sleep apnea, heart disease, or mobility issues, this could be a major shift in both healthcare and household budgeting. Here is what you need to know about the bridge, and how it could help you access the care you need.
